This retrospective chart review study investigates the long-term clinical outcome of Biodentine® (Tricalcium silicate) as a medicament for pulpotomy in primary molars. Data in this retrospective study was collected from the dental records of all patients that had at least one primary molar receive pulpotomy treatment (CDT code: D3221) between 01 July 2012 and 01 July 2015. This data includes child's age, medical history, dental history, dental radiographs, pulpotomy procedure details and follow-up clinical notes. Kaplan-Meier Estimate was used to measure the fraction of successful pulpotomy procedures for up to 24 months. A total of 1758 pulpotomy procedures were performed on 1032 patients in our institute in the three-year period and 21.4% of them (N = 376) had follow-up dental records that qualified for the study. Eleven teeth out of 376 teeth were excluded from the statistical analysis due to loss of/broken stainless steel crowns (3.1%). Seventeen pulpotomy failures were identified out of the remaining 365 procedures. The survival probablity of using Biodentine® as a pulpotomy medicament is 96.3% for 18-month follow-up and 95.4% for 24-month follow-up. Biodentine®, a tricalcium silicate formulation, used as a pulpotomy medicament demonstrates a high clinical success rate (95.4%) over a 24-month peroid in primary molars.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.22514/jocpd.2024.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow-Up.
Int J Paediatr Dent
December 2024
Private Practitioner at Pediatric Dental Care Associates, Las Vegas, Nevada, USA.
Background: In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth.
Aims: To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months.
Design: Children aged 4-9 years, with deep dentinal caries (ICDAS 4-6) in primary molars, having no history of spontaneous pain or signs of non-vitality were included in the study.
Microtomographic and histological evaluation of two bioceramics as pulp capping agents in vivo.
Acta Odontol Latinoam
September 2024
Laboratorio de Bioingeniería de Tejidos, División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México.
Maintaining pulp vitality and function is a priority of the medicaments employed in pulp therapy to preserve tooth integrity. Aim: This study evaluated inflammatory response and reparative dentin bridge formation after direct pulp capping with two different bioceramics. Materials and Method: This was an in vivo controlled experimental study on 12 male Wistar rats.
View Article and Find Full Text PDFA Systematic Review and Meta-analysis of Regenerative Pulpotomy in the Treatment of Vital Primary Teeth.
Eur J Paediatr Dent
September 2024
Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.) University of Palermo Italy.
Article Synopsis
- The study aimed to compare the effectiveness of regenerative pulpotomy versus devitalising or preservative pulpotomy for treating vital pulp exposure in primary teeth.
- A thorough data search was conducted across multiple databases, with studies assessed for quality using the Cochrane Collaboration Tool and Minors Checklist, followed by a meta-analysis.
- The findings suggested that MTA is a more effective treatment option than FC and FS, showing a lower risk of failure, while BD also showed promising results as a pulpotomy medicament.
Comparative Evaluation of Success of NeoPutty Mineral Trioxide Aggregate ® with Formocresol as Pulpotomy Medicaments in Primary Molars: A Clinical Study.
Indian J Dent Res
April 2024
Department of Pediatric and Preventive Dentistry, Saveetha Dental College, SIMATS, Chennai, Tamil Nadu, India.
Objective: This clinical study was aimed to investigate the clinical and radiographic outcomes of NeoPutty MTA ® (Nusmile), a novel mineral trioxide aggregate (MTA) pulpotomy material, in primary teeth of children aged 4-6 years.
Methods: An in vivo study was done in children aged 4-6 years old. A total of 50 primary second molar teeth were included in the study, with 25 of them undergoing treatment with formocresol (FC) and 25 receiving treatment with NeoPutty MTA ® .
Hyaluronic acid as a pulpotomy material in primary molars: an up to 30 months retrospective study.
BMC Oral Health
June 2024
Department of Paediatric Dentistry, Faculty of Dentistry, Marmara University, Istanbul, Türkiye, 34854, Turkey.
Background: The aim of this retrospective study was to determine the long-term clinical and radiographic success of our previous randomized clinical trial and to compare the success of hyaluronic acid, with the widely used formocresol and ferric sulphate agents.
Methods: This retrospective study is the extension of the 1-year survey of our randomized clinical trial that had compared the effectiveness of a hyaluronic acid pulpotomy over formocresol and ferric sulphate pulpotomies and included clinical and radiographic evaluations with a follow-up period of over 24 months for 44 children who applied to our clinic between May 2019 and September 2019. Long-term clinical and radiographic data were obtained from the periodic files of our department, wherein each tooth's file was examined to identify any clinical and radiographic findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!